BioLineRx Receives Orphan Drug Designation for Novel Stem Cell Mobilization Treatment BKT-140/BL-8040 previously received Orphan Drug Designation for treatment of Acute Myeloid Leukemia. BKT-140/BL-8040 is expected to commence Phase 1 trial in stem cell mobilization in Q2 2014, and top-line results are expected in H2 2014.
BioLineRx Announces Positive Preclinical Results for Novel Treatment for Chronic Myeloid Leukemia BKT-140/BL-8040 study published in Molecular Cancer Therapeutics. BKT-140/BL-8040 is currently undergoing a Phase 2 trial for acute myeloid leukemia (AML) and is expected to commence a Phase 1 trial in stem cell mobilization in Q2 2014; top-line results from both trials are expected [...]
BioLineRx Announces Issuance of United States Patent Covering Use of BKT-140/BL-8040 in Immunotherapy BKT-140/BL-8040 is currently undergoing a Phase 2 trial for acute myeloid leukemia (AML) and is expected to commence a Phase 1 trial in stem cell mobilization in Q2 2014.
BioLineRx Announces Investigator-Initiated Study for Novel Chronic Myeloid Leukemia Treatment A phase 1/2 study will assess the effect of BKT-140/BL-8040 in combination with standard therapy.
BioLineRx Receives Approval to Commence Phase 1 Trial for Novel Stem Cell Mobilization Treatment The phase 1 trial of BKT-140/BL-8040 is expected to begin in Q3 2014, with results expected in late 2014 or early 2015. BKT-140/BL-8040 is also in Phase 2 for AML, with results expected in early 2015.
BioLineRx Doses First Patient for BKT-140/BL-8040’s Second Indication as Novel Stem Cell Mobilization Treatment The results from the phase 1 trial expected by end of 2014 or early 2015. BKT-140/BL-8040 is also in the midst of a Phase 2 trial for AML, with results expected in early 2015.
BioLineRx Presents Positive Preclinical Results in Treatment for AML Patients with FLT3 Mutations The results for this additional indication for BKT-140/BL-8040 will be presented at the Society of Hematologic Oncology (SOHO) Annual Meeting. BKT-140/BL-8040 is also undergoing Phase 2 study in AML, with the final results expected in early 2015. It is also in a [...]
BioLineRx Files Protocol Amendment to Phase 2 Study for AML Treatment based on Encouraging Efficacy and Strong Safety Profile The amendment will include the testing of higher doses, resulting in an increase in the total study population to 70 patients. The changes were unanimously recommended by the Clinical Advisory Board.
BioLineRx Reports Positive Data from Ongoing Phase 2a Study for AML Treatment at ASH conference Data show six-fold increase in mobilization of AML cells from bone marrow; Treatment with BL-8040 as single agent led to 70% decrease in AML cells in bone marrow and 3.5-fold increase in AML cell apoptosis
BioLineRx Presents Multi-Year Clinical Development Plan for its BL-8040 Hematological Cancer Therapeutic Platform BioLineRx Presents Multi-Year Clinical Development Plan for its BL-8040 Hematological Cancer Therapeutic Platform Clinical trials in three additional indications for BL-8040 to be initiated in 2015 Development strategy presented today at BioLineRx investor meeting in New York
